# Deferasirox in Treating Patients With Very Low, Low, or Intermediate-Risk Red Blood Cell Transfusion Dependent Anemia or Myelodysplastic Syndrome

> **NCT02943668** · PHASE2 · TERMINATED · sponsor: **Fred Hutchinson Cancer Center** · enrollment: 2 (actual)

## Conditions studied

- Anemia
- Myelodysplastic Syndrome

## Interventions

- **DRUG:** Deferasirox
- **OTHER:** Laboratory Biomarker Analysis

## Key facts

- **NCT ID:** NCT02943668
- **Lead sponsor:** Fred Hutchinson Cancer Center
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2017-03-02
- **Primary completion:** 2018-12-17
- **Final completion:** 2018-12-17
- **Target enrollment:** 2 (ACTUAL)
- **Why stopped:** Terminated due to low accrual
- **Last updated:** 2020-07-01

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02943668

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02943668, "Deferasirox in Treating Patients With Very Low, Low, or Intermediate-Risk Red Blood Cell Transfusion Dependent Anemia or Myelodysplastic Syndrome". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT02943668. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*